913952-59-7

Usage

Uses

Used in Organic Chemistry:
6-Chloro-2-phenyl-pyrimidine-4-carboxylic acid is used as a versatile compound in organic chemistry for its ability to participate in synthesis reactions, contributing to the creation of new molecules.
Used in Pharmaceutical Industry:
6-Chloro-2-phenyl-pyrimidine-4-carboxylic acid is used as a key intermediate in the pharmaceutical industry for its role in developing potential drugs and pharmaceuticals, highlighting its importance in the discovery and synthesis of novel therapeutic agents.
Used in Drug Development:
6-Chloro-2-phenyl-pyrimidine-4-carboxylic acid is used as a building block in drug development, facilitating the design and synthesis of innovative medications with potential therapeutic applications.

Upstream product

• 325685-75-4 4-Chloro-6-hydroxymethyl-2-phenylpyrimidine 
• 618-39-3 benzamidin 
• 339278-89-6 6-methoxymethyl-2-phenylpyrimidin-4-ol 
• 325685-59-4 4-chloro-6-methoxymethyl-2-phenylpyrimidine 
• 1670-14-0 benzamidine monohydrochloride 

Downstream Products

• 1159501-69-5 6-((S)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carboxylic acid 
• 1159501-91-3 4-((S)-2-((6-chloro-2-phenylpyrimidine-4-carbonyl)amino)-4-diethoxyphosphorylbutyryl)piperazine-1-carboxylic acid butyl ester 
• 1021703-38-7 4-{(S)-4-tert-butoxycarbonyl-2-[(6-chloro-2-phenyl-pyrimidine-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid butyl ester 
• 913947-47-4 C₃₀H₃₄N₆O₆ 
• 913952-10-0 C₂₅H₃₂N₆O₇ 
• 913948-91-1 4-{(S)-4-tert-butoxycarbonyl-2-[(6-cyclopropyl-2-phenyl-pyrimidine-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 
• 913948-88-6 4-{(S)-4-tert-butoxycarbonyl-2-[(6-isopropyl-2-phenyl-pyrimidine-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 
• 913951-70-9 4-{(S)-4-tert-butoxycarbonyl-2-[(2-phenyl-6-pyridin-4-yl-pyrimidine-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 
• 913951-69-6 4-{(S)-4-tert-butoxycarbonyl-2-[(2-phenyl-6-pyridin-3-yl-pyrimidine-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 
• 913948-93-3 4-{(S)-4-tert-butoxycarbonyl-2-[(2,6-diphenyl-pyrimidine-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 
• 913952-11-1 C₂₆H₃₂N₆O₈ 
• 913950-00-2 4-((S)-4-tert-butoxycarbonyl-2-{[6-(3-hydroxy-prop-1-ynyl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-butyryl)-piperazine-1-carboxylic acid ethyl ester 
• 913947-39-4 C₂₇H₃₇N₇O₆ 
• 913947-43-0 C₂₉H₃₉N₇O₇ 

Relevant academic research and scientific papers

4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel

Recent post hoc analyses of several clinical trials with P2Y12 antagonists showed the need for new molecules being fully efficacious as antiplatelet agents and having a reduced propensity to cause major bleeding. We have previously reported the discovery of the 2-phenylpyrimidine-4-carboxamide analogs as P2Y12 antagonists with nanomolar potency in the disease-relevant platelet aggregation assay in human plasma. Herein we present the optimization steps that led to the discovery of clinical candidate ACT-246475 (30d). The key step was the replacement of the carboxylic acid functionality by a phosphonic acid group which delivered the most potent molecules of the program. In addition, low in vivo clearance in rat and dog was achieved for the first time. Since the bioavailability of 30d was low in rat and dog, we developed the bis((isopropoxycarbonyl)oxy)methyl ester prodrug (ACT-281959, 45). Compound 30d showed efficacy in the rat ferric chloride thrombosis model when administered intravenously as parent or orally as its prodrug 45. Moreover, 30d displays a wider therapeutic window as compared to clopidogrel in the rat surgical blood loss model.

Malononitrile: A versatile d1-synthon for the synthesis of hetero-aromatic carboxylic acid derivatives

A convenient one-pot synthesis of heteroaromatic carboxylic acid derivatives from malononitrile substituted heteroaromatic compounds, namely pyridines, pyrimidines, and 1,3,5-triazines is described. In this procedure, the oxidation of malononitriles with

Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y12 antagonists for inhibition of platelet aggregation

2-Phenyl-pyrimidine-4-carboxamide analogs were identified as P2Y 12 antagonists. Optimization of the carbon-linked or nitrogen-linked substituent at the 6-position of the pyrimidine ring provided compounds with excellent ex vivo potency in the

2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES

The present invention relates to 2-phenyl-4-cyclopropyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular a

2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS

The invention relates to 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. Formula (I).

2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR

The invention relates to 2-phenyl-6-aminbcarbonyl-pyrimidinc derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. Formula (1).

2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES

The present invention relates to 2-phenyl-4-cyclopropyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular a